

## APPENDIX

### Appendix References

- S1. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. the NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS* **2002**; 16:569–77.
- S2. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. and the AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study. *J Acquir Immune Defic Syndr* **2005**; 39:307–12.
- S3. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. and the ACTG A5108; Team. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. *AIDS* **2006**; 20:725–9.
- S4. Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics, 2006.
- S5. Kiser JJ, Gerber JG, Paredes JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. *J Acquir Immune Defic Syndr* **2008**; 47: 570–8.
- S6. Busti AJ, Bain AM, Hall RGH, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. *J Cardiovasc Pharmacol* **2008**; 51:605–10.